Patent classifications
A61L27/26
INJECTABLE HYDROGEL COMPOSITION HAVING ENDOGENOUS PROGENITOR OR STEM CELL RECRUITMENT AND INDUCTION OF VASCULAR DIFFERENTIATION OF RECRUITED CELLS
The present invention relates to an injectable hydrogel composition having the recruitment of endogenous progenitors or stem cells and the induction of vascular differentiation of recruited cells, and more specifically to an injectable hydrogel composition having the recruitment of endogenous progenitors or stem cells and the induction of vascular differentiation of recruited cells, which consists of: a first solution including anionic hyaluronic acid into which a vascular differentiation inducing factor is introduced; and a second solution including a cationic material, wherein a stem cell recruitment factor is further included in the first solution and/or the second solution, and wherein a hydrogel is formed by electrostatic interaction.
In the hydrogel composition of the present invention, it was confirmed that the stem cell recruitment factor was released from the injected hydrogel, and endogenous progenitor cells/stem cells were recruited in the hydrogel, and the induction of angiogenesis was promoted by differentiating into vascular cells by the vascular differentiation inducing factor chemically introduced into hyaluronic acid. In particular, it was confirmed that when the vascular differentiation inducing factor was chemically introduced into hyaluronic acid, a high angiogenesis-inducing effect was observed. Therefore, the hydrogel composition of the present invention has excellent recruitment of endogenous progenitor cells/stem cells and induction of vascular differentiation, and thus, it can be effectively applied to various tissue regenerations and wound treatments in addition to the formation of blood vessels.
METHOD FOR PRODUCING A 3D-PRINTED TISSUE SUBSTITUTE
A method for producing a 3D-printed tissue substitute is disclosed, utilizing a 3D printing device including a tank including a yield stress fluid in which the material is printed, the printing material delivered by the cartridge includes polyvinyl alcohol and gelatin, the method including a step following which, after printing the material in the yield stress fluid, a printed intermediate device is solidified in the yield stress fluid by lowering the temperature of the tank. The intermediate device is removed from the tank, rinsed and dried in order to obtain the tissue substitute.
METHOD FOR PRODUCING A 3D-PRINTED TISSUE SUBSTITUTE
A method for producing a 3D-printed tissue substitute is disclosed, utilizing a 3D printing device including a tank including a yield stress fluid in which the material is printed, the printing material delivered by the cartridge includes polyvinyl alcohol and gelatin, the method including a step following which, after printing the material in the yield stress fluid, a printed intermediate device is solidified in the yield stress fluid by lowering the temperature of the tank. The intermediate device is removed from the tank, rinsed and dried in order to obtain the tissue substitute.
ERYTHROPOIETIN COMPOSITIONS AND METHODS OF USE
This document relates to compositions containing one or more erythropoietin (EPO) polypeptides. For example, this document provides thermoresponsive compositions containing one or more EPO polypeptides and methods for using such thermoresponsive compositions as a delivery system to deliver one or more EPO polypeptides to desired tissue (e.g., to treat a nerve injury and/or a wound). In some cases, thermoresponsive compositions containing one or more EPO polypeptides can be administered (e.g., locally administered) to a mammal having a nerve injury to treat the nerve injury (e.g., to promote wound healing). In some cases, thermoresponsive compositions containing one or more EPO polypeptides can be administered (e.g., locally administered) to a mammal having a wound to treat the wound (e.g., to promote wound healing).
ERYTHROPOIETIN COMPOSITIONS AND METHODS OF USE
This document relates to compositions containing one or more erythropoietin (EPO) polypeptides. For example, this document provides thermoresponsive compositions containing one or more EPO polypeptides and methods for using such thermoresponsive compositions as a delivery system to deliver one or more EPO polypeptides to desired tissue (e.g., to treat a nerve injury and/or a wound). In some cases, thermoresponsive compositions containing one or more EPO polypeptides can be administered (e.g., locally administered) to a mammal having a nerve injury to treat the nerve injury (e.g., to promote wound healing). In some cases, thermoresponsive compositions containing one or more EPO polypeptides can be administered (e.g., locally administered) to a mammal having a wound to treat the wound (e.g., to promote wound healing).
TISSUE REPAIR IMPLANT AND COMPOSITIONS AND METHOD OF IMPLANTATION
A tendon/ligament repair implant for treatment of tears or lesions of tendons and ligaments, including capsular reconstruction, and compositions for delivering calcium and/or phosphate ions in combination with a collagen solution that can be placed between soft tissue and bone to facilitate healing of the soft tissue-bone interface are provided. The implant may incorporate features of rapid deployment and fixation by arthroscopic means that complement current procedures; tensile properties that result in desired sharing of anatomical load between the implant and native tendon during rehabilitation, or, in situations where the native tissue cannot be repaired tensile properties that provide for substitution of the native tissue selected porosity and longitudinal pathways for tissue in-growth; and may include an at least partially bioabsorbable construction to provide transfer of additional load to new tendon-like tissue and native tendon over time. The compositions can be pre-dried into a thin sheet of material and delivered as a pre-formed matrix, or as a gel or paste which sets in place to form the matrix between the soft tissue and bone.
TISSUE REPAIR IMPLANT AND COMPOSITIONS AND METHOD OF IMPLANTATION
A tendon/ligament repair implant for treatment of tears or lesions of tendons and ligaments, including capsular reconstruction, and compositions for delivering calcium and/or phosphate ions in combination with a collagen solution that can be placed between soft tissue and bone to facilitate healing of the soft tissue-bone interface are provided. The implant may incorporate features of rapid deployment and fixation by arthroscopic means that complement current procedures; tensile properties that result in desired sharing of anatomical load between the implant and native tendon during rehabilitation, or, in situations where the native tissue cannot be repaired tensile properties that provide for substitution of the native tissue selected porosity and longitudinal pathways for tissue in-growth; and may include an at least partially bioabsorbable construction to provide transfer of additional load to new tendon-like tissue and native tendon over time. The compositions can be pre-dried into a thin sheet of material and delivered as a pre-formed matrix, or as a gel or paste which sets in place to form the matrix between the soft tissue and bone.
3D HUMAN LIVER ORGAN MODEL CONSTRUCTING METHOD, 3D HUMAN LIVER ORGAN MODEL AND USE THEREOF
Provided is a 3D human liver organ model constructing method, comprising: preparing human primary liver cells, or mixed cells of same and liver non-parenchymal cells, or human liver cancer cell lines into a single cell suspension, and mixing the single cell suspension with a matrix material to obtain a mixed cell suspension; inoculating the mixed cell suspension into cultivation micropores of a 3D organ-on-a-chip, and carrying out cultivation at 37° C. to obtain a gelled 3D organ-on-a-chip; adding a culture medium into liquid storage holes of the organ-on-a-chip, and carrying out cultivation to obtain a 3D human liver organ model. Compared with other 2D human liver organ models, the constructed 3D human liver organ model has significantly enhanced response sensitivity to hepatotoxic drugs, and shows stronger hepatotoxic damage effect for reported hepatotoxic drugs. Compared with an animal model, the 3D human liver organ model can effectively eliminate the screening difference caused by species difference.
ELECTROSPUN STRUCTURES FOR M1/M2 MACROPHAGE MODULATION AND METHODS OF MAKING AND USING THE SAME
Disclosed herein are methods of controlling a composition of M1/M2 macrophages in a wound of a subject. The method can include applying an electrospun structure to the wound, wherein the electrospun structure comprises a polymer, wherein the polymer comprises an alpha-hydroxy acid, and keeping the electrospun structure on the wound for a time period. The presence of the electrospun structure on the wound causes an increase in presence of M2 macrophages relative to M1 macrophages, which can, in turn, promote healing of the wound.
ELECTROSPUN STRUCTURES FOR M1/M2 MACROPHAGE MODULATION AND METHODS OF MAKING AND USING THE SAME
Disclosed herein are methods of controlling a composition of M1/M2 macrophages in a wound of a subject. The method can include applying an electrospun structure to the wound, wherein the electrospun structure comprises a polymer, wherein the polymer comprises an alpha-hydroxy acid, and keeping the electrospun structure on the wound for a time period. The presence of the electrospun structure on the wound causes an increase in presence of M2 macrophages relative to M1 macrophages, which can, in turn, promote healing of the wound.